A new approach using liquid biopsy and comprehensive genomic profiling (CGP) is offering hope for patients diagnosed with Cancer of Unknown Primary (CUP). This method, which analyzes a patient's blood, can identify specific mutations like the BRAF mutation, guiding targeted therapies and potentially extending survival. While typically self-financed, this technology is also being integrated into routine diagnostics for other cancers, such as non-small cell lung cancer, in regions like the United Kingdom and Hong Kong. AI
RANK_REASON Article discusses a diagnostic technology and its application to a specific medical condition, not a new frontier AI release.
- adenocarcinoma
- BRAF mutation
- comprehensive genomic profiling
- Hong Kong
- liquid biopsy
- National Health Service
- Professor El Helali
- United Kingdom
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →